Biote (BTMD) Change In Receivables : $-2.3 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biote Change In Receivables?

Biote's change in receivables for the quarter that ended in Dec. 2024 was $0.3 Mil. It means Biote's Accounts Receivable declined by $0.3 Mil from Sep. 2024 to Dec. 2024 .

Biote's change in receivables for the fiscal year that ended in Dec. 2024 was $-2.3 Mil. It means Biote's Accounts Receivable increased by $2.3 Mil from Dec. 2023 to Dec. 2024 .

Biote's Accounts Receivable for the quarter that ended in Dec. 2024 was $7.6 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Biote's Days Sales Outstanding for the three months ended in Dec. 2024 was 13.97.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biote's liquidation value for the three months ended in Dec. 2024 was $-172.1 Mil.

Biote Change In Receivables Historical Data

The historical data trend for Biote's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biote Change In Receivables Chart

Biote Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-1.48

-0.75

-1.56

-0.51

-2.27

Biote Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial											3.33	-1.33	-0.36	-0.87	0.28

Biote Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.3 Mil.

Biote (NAS:BTMD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biote's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	7.631	/	49.834	*	91
=	13.97

2. In Ben Graham's calculation of liquidation value, Biote's accounts receivable are only considered to be worth 75% of book value:

Biote's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	39.342	-	224.57	+	0.75 * 7.631	+	0.5 * 14.845
=	-172.1

Biote Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biote's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biote Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Biote Corp (NAS:BTMD) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1875 West Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038

Website

https://www.biote.com

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.

Executives

Guines Llc	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Stephen Mark Cone	director	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Marc D Beer	director	C/O AEGERION PHARMACEUTICALS, 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Andrew R Heyer	director, officer: President and Director	501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Mary Elizabeth Conlon	officer: General Counsel	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Daniel M. Friedberg	10 percent owner	C/O SAGARD CAPITAL, 325 GREENWICH AVENUE, GREENWICH CT 06830
Anil K Shrivastava	10 percent owner	200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Michael David Braner	10 percent owner	200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
325 Capital Llc	10 percent owner	757 THIRD AVENUE, 20TH FLOOR, NEW YORK NY 10017
Mary Joan Puncochar	officer: Chief Commercial Officer	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Samar Jagat Kamdar	officer: Chief Financial Officer	7042 CORONADO AVE., DALLAS TX 75214
Roystone Capital Management Lp	10 percent owner	780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Debra L Morris	director	11620 WILSHIRE BOULEVARD, SUITE 1000, LOS ANGELES CA 90025
Roystone Capital Holdings Llc	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Teresa Sue Weber	director, officer: Chief Executive Officer	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038